Zusammenfassung
Eine wirksame neoadjuvante Chemotherapie kann bei ausgesuchten Patienten mit kolorektalem
Karzinom und hepatischer Metastasierung zu sekundärer Resektabilität führen. Wir berichten
über einen Patienten mit einem retroperitonealem lokoregionären Rezidiv eines Kolonkarzinoms,
der mit einer Kombinationstherapie mit infusionalem 5-Fluorouracil, Folinsäure, Oxaliplatin
und Cetuximab behandelt wurde. Nach 12 Wochen Therapiedauer konnte ein partielles
Tumoransprechen erzielt werden. Weitere 3 Wochen später wurde der Patient operiert
und der Tumor ohne perioperative Komplikationen komplett reseziert. Diese Kasuistik
zeigt, dass eine neoadjuvante Behandlung mit molekular gezielten Therapeutika in Kombination
mit Chemotherapie ebenfalls bei ausgesuchten Patienten mit lokoregionärem Rezidiv
eine sekundäre kurative operative Sanierung erlauben kann.
Abstract
Some patients with initially unresectable hepatic colorectal cancer metastases can
be effectively treated with neoadjuvant chemotherapy to allow operative resection
in curative intent. Here, we report on a patient with unresectable locoregional recurrence
of colon cancer, which was down-staged using combination chemotherapy with infusional
5-fluorouracil, folinic acid, oxaliplatin and cetuximab. After 12 weeks of therapy
a partial response was documented and 3 weeks later the tumor was completely resected
without increased perioperative morbidity. Therefore, neoadjuvant treatment with molecular
targeted agents in combination with chemotherapy can also be an option to enable selected
patients with locoregional recurrence to undergo surgical resection in curative intent.
Schlüsselwörter
Kolonkarzinom - lokoregionäres Rezidiv - neoadjuvante Therapie - molekular gezielte
Therapie - Chirurgie
Key words
colon cancer - locoregional recurrence - neoadjuvant treatment - molecular targeted
therapy - surgery
References
1
Goldberg R M, Fleming T R, Tangen C M. et al .
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence
and success rates after resection. Eastern Cooperative Oncology Group, the North Central
Cancer Treatment Group, and the Southwest Oncology Group.
Ann Intern Med.
1998;
129
27-35
2
Bowne W B, Lee B, Wong W D. et al .
Operative salvage for locoregional recurrent colon cancer after curative resection:
an analysis of 100 cases.
Dis Colon Rectum.
2005;
48
897-909
3
Hurwitz H, Fehrenbacher L, Novotny W. et al .
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer.
N Engl J Med.
2004;
350
2335-2342
4
Cunningham D, Humblet Y, Siena S. et al .
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic
colorectal cancer.
N Engl J Med.
2004;
351
337-345
5
Ellis L M, Curley S A, Grothey A.
Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.
J Clin Oncol.
2005;
23
4853-4855
6
Gruenberger B, Scheithauer W, Tamandl D. et al .
Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with respectable
colorectal cancer liver metastases. ASCO Annual Meeting Proceedings Part I.
J Clin Oncol.
2007;
25 (20 Suppl)
A-4060
7
D’Angelica M, Kornprat P, Gonen M. et al .
Lack of evidence for increased operative morbidity after hepatectomy with perioperative
use of bevacizumab: a matched case-control study.
Ann Surg Oncol.
2007;
14
759-765
8
Van Cutsem E, Nowacki M, Lang I. et al .
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in
the first-line treatment of patients with metastatic colorectal cancer (mCRC): the
CRYSTAL trial. ASCO Annual Meeting Proceedings Part I.
J Clin Oncol.
2007;
25 (20 Suppl)
A-4000
9
Bokemeyer C, Bondarenko I, Makhson A. et al .
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment
of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Annual
Meeting Proceedings Part I.
J Clin Oncol.
2007;
25 (20 Suppl)
A-4035
10
Borner M, Mingrone W, Koeberle D. et al .
The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in
first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II
trial of the Swiss Group for Clinical Cancer Research (SAKK). ASCO Annual Meeting
Proceedings Part I.
J Clin Oncol.
2006;
24 (20 Suppl)
A-3551
11 Andre T, Tabernero J, Van Cutsem E. et al .Phase II study with cetuximab plus FOLFOX-4
in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic
colorectal cancer (mCRC): Final results. Orlando, FL, USA; Gastrointestinal Cancers
Symposium 2007: A-334
12
Hofheinz R D, Horisberger K, Woernle C. et al .
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and
radiotherapy as neoadjuvant therapy for rectal cancer.
Int J Radiat Oncol Biol Phys.
2006;
66
1384-1390
13
Arnold D, Hipp M, Liersch T. et al .
Cetuximab, capecitabine, and oxaliplatin (Cet-CapOx) with concurrent radiotherapy
(RT) in advanced rectal cancer (RC): Results of a phase I/II trial. ASCOAnnual Meeting
Proceedings Part I.
J Clin Oncol.
2007;
25 (20 Suppl)
A-4042
PD Dr. Jörg Trojan
Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe-Universität
Theodor-Stern-Kai 7
D-60590 Frankfurt
Phone: ++ 49/69/63 01 - 78 60
Fax: ++ 49/69/63 01 - 8 37 76
Email: trojan@em.uni-frankfurt.de